Eyevensys closes €1.6m Seed Funding to develop its EyeCET Platform
The EyeCET platform allows the creation of a bio therapeutic factory in the eye for the treatment of various eye diseases
Paris (France), January 2012 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral technology that allows a safe local sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases, announces that it has closed its seed round of financing. The round was led by the Bpifrance owned fund Innobio, CapDecisif Management and Inserm Transfert. In conjunction with the closing of the seed funding, Mrs Catherine Boule from CapDecisif Management and Mrs Chahra Louafi from Inserm Transfert have joined Eyevensys Board of Directors.
The funds will be used to further develop Eyevensys’ EyeCET platform, the first non-viral technology that uses a proprietary injection and electroporation system named ETIS (Electro-Transfection Injection System) to deliver plasmids encoding for the production of therapeutic proteins in the ciliary muscle of the eye.
Francine Behar-Cohen, MD, PhD, Founder and Chief Scientific Officer of Eyevensys, said: “The idea behind the EyeCET platform is to provide the patients with long lasting ocular therapeutics without having to go through the current treatments that can be very invasive and trigger severe side effects. We are grateful that Innobio, CapDecisif Management and Inserm Transfert share our excitement about the potential of EyeCET’s technology.”